Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HealthCare Royalty Partners

http://www.healthcareroyalty.com/

Latest From HealthCare Royalty Partners

Bayer Extends Afrin Line With First OTC Oxymetazoline Spray In US For Children Under 6

Children’s Afrin regular and no-drip formulations reach US stores with consumers having choices between dozens of oxymetazoline nasal sprays available under an FDA OTC monograph. But products indicated for children was limited to one, Mucinex Childrens Stuffy Nose, and it’s for children 6 and up.

OTC Drugs Launches

Euro Q3 Consumer Health Earnings Preview: Helm Changes, Investor Questions, Results Debut

Major Europe-based consumer health players Reckitt, Bayer, Sanofi and Haleon feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q3 2022 results over the coming weeks.

Europe Sales & Earnings

Defend-Eeze Launches In US Zinc Cold Remedy Market

Vespyr, incorporated in December 2021 after operating as Nurya when it acquired Cold-Eeze from Mylan in May that year, offers Defend-Eeze in lozenges containing echinacea, elderberry and vitamins C and D3 in addition to zinc.

Ingredients Launches

Stock Watch: Binary Second-Quarter Oncology And COVID-19 Trends

Oncology drug sales plummeted during the pandemic leading to a backlog of untreated patients that lingered even after the impact of COVID-19 drugs. While Q2 reports suggest this cancer backlog is now being addressed, the contrasting fates of vaccines and treatments for SARS-CoV-2 are actually turning out to be opaquer than expected. 

Stock Watch Commercial
See All

Company Information

  • Industry
  • Miscellaneous
UsernamePublicRestriction

Register